Q0100000
Quinidine sulfate
European Pharmacopoeia (EP) Reference Standard
동의어(들):
Quinidine sulfate salt dihydrate
로그인조직 및 계약 가격 보기
크기 선택
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C40H48N4O4 · H2O4S · 2H2O
CAS 번호:
Molecular Weight:
782.94
MDL number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24
Grade
pharmaceutical primary standard
API family
quinidine
제조업체/상표
EDQM
mp
212-214 °C (dec.) (lit.)
응용 분야
pharmaceutical (small molecule)
형식
neat
저장 온도
2-8°C
SMILES string
[H]O[H].[H]O[H].OS(O)(=O)=O.[H][C@]1(CN2CCC1C[C@]2([H])[C@@H](O)c3ccnc4ccc(OC)cc34)C=C.[H][C@]5(CN6CCC5C[C@]6([H])[C@@H](O)c7ccnc8ccc(OC)cc78)C=C
InChI
1S/2C20H24N2O2.H2O4S.2H2O/c2*1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;1-5(2,3)4;;/h2*3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;(H2,1,2,3,4);2*1H2/t2*13-,14?,19-,20+;;;/m11.../s1
InChI key
ZHNFLHYOFXQIOW-WFTMRWCJSA-N
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
애플리케이션
Quinidine sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
생화학적/생리학적 작용
Class IA antiarrhythmic; potassium channel blocker.
포장
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
기타 정보
Sales restrictions may apply.
신호어
Warning
유해 및 위험 성명서
예방조치 성명서
Hazard Classifications
Acute Tox. 4 Oral
Storage Class Code
11 - Combustible Solids
WGK
WGK 1
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
Motoya Suzuki et al.
Xenobiotica; the fate of foreign compounds in biological systems, 44(11), 1039-1045 (2014-05-21)
1. This study was aimed to characterize gastrointestinal absorption of digoxin using wild-type (WT) and multidrug resistance protein 1a [mdr1a; P-glycoprotein (P-gp)] knockout (-/-) rats. 2. In WT rats, the area under the plasma concentration-time curve (AUC) of oral digoxin
Yuki Ogawa et al.
European journal of pediatrics, 174(4), 509-518 (2014-09-25)
This study aimed to determine the population pharmacokinetics of doxapram in low-birth-weight (LBW) infants. A total of 92 serum concentration measurements that were obtained from 34 Japanese neonates were analyzed using nonlinear mixed-effect modeling (NONMEM). Estimates generated by NONMEM indicated
Maria Addolorata Saracino et al.
Journal of pharmaceutical and biomedical analysis, 95, 61-67 (2014-03-19)
A rapid and reliable analytical method has been developed to quantify the melatonergic antidepressant agomelatine in three matrices, and namely saliva, plasma and dried blood spots. The method is based on the use of liquid chromatography with fluorimetric detection exploiting
Mikiko Tsukimoto et al.
Biopharmaceutics & drug disposition, 36(1), 15-33 (2014-09-30)
Aliskiren is a substrate for P-glycoprotein (P-gp) and is metabolized via cytochrome P450 3A4 (CYP3A4). The aim of the present study was to assess whether P-gp influenced the pharmacokinetics of aliskiren and also if drug-drug interactions (DDIs) mediated through P-gp
Laura Kervezee et al.
The AAPS journal, 16(5), 1029-1037 (2014-06-12)
Nearly all bodily processes exhibit circadian rhythmicity. As a consequence, the pharmacokinetic and pharmacodynamic properties of a drug may also vary with time of day. The objective of this study was to investigate diurnal variation in processes that regulate drug
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.